

Certificate of Analysis

PI3 Kinase (p120γ)

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-558, 14-558-K, 14-558M

Parent Lot # 2298365

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant full-length human PI3 kinase (p120γ) expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 92.4% by SDS-PAGE and Coomassie blue staining. MW = 130kDa.

Specific Activity (Parent lot# 2298365): 34U/mg, where one unit of PI3 Kinase (p120γ) activity is defined as 1nmol phosphatidylinositol 3,4,5-trisphosphate formed per minute at 22°C with a final ATP concentration of 100μM.

Formulation: 1.481mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 10% glycerol, 0.1mM EGTA, 2mM DTT.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**


Quality Control Testing

Kinase Assay: 0.9–9.5ng of this enzyme phosphorylated 10μM phosphatidylinositol 4, 5-bisphosphate in the assay referenced on page two.



MS Tryptic Fingerprint: Confirmed product identity as PI3 Kinase (p120γ) with the translated sequence listed on page two.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3μg of active PI3 kinase (p120γ).



Certificate of Analysis

Eurofins PI3 Kinase Homogeneous Time-resolved Fluorescence (HTRF) Class I Reagent Kits

The following Eurofins kits are suitable for use with this enzyme:

Cat. No	Kit Description
33-016	PI3 Kinase 4-Step Assay Reagent 1-Plate Kit
33-017	PI3 Kinase 4-Step Assay Reagent 5-Plate Kit
33-036	PI3 Kinase 4-Step Assay Reagent Kit (10000 wells)
33-037	PI3 Kinase 4-Step Assay Reagent Kit (50000 wells)
33-040	PI3 Kinase 3-Step Assay Reagent Kit (384 wells)
33-041	PI3 Kinase 3-Step Assay Reagent Kit (1920 wells)
33-047	PI3 Kinase 3-Step Assay Reagent Kit (10000 wells)

Kits 33-016, 33-017, 33-036 and 33-037 provide reagents and assay details for the Eurofins standard 4-step HTRF assay. This assay format is suitable for the majority of small and medium throughput screening work. The 3-step HTRF assay (kits 33-040, 33-041, 33-047) was introduced to reduce the number of assay steps to aid high throughput screening. Items 33-040 and 33-041 are intended as introductory kits for 3-step procedure work up. Please contact us for any further information regarding different kit formats (discoveryservices@eurofins.com).

Certificate of Analysis

P13 Kinase (p120y) Sequence Information

<u>Protein</u>	human P13 Kinase (p120y)
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M34 of the recombinant protein is equivalent to M1 of human P13 Kinase (p120y)
<u>Accession number</u>	GenBank AF327656. The recombinant protein contains the amino acid substitution R459Q with respect to this accession number. This conflict is reported in GenBank XM_027912. The residue coordinates in the native sequence are given.

Recombinant P13 Kinase (p120y) amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMGSGI RPCMELENYK QPVVLRDNC RRRRRMKPRS
61 AAASLSSMEL IPIEFVLPTS QRKCKSPETA LLHVAGHGNV EQMKAQVWLR ALETSAADF
121 YHRLGPHHFL LLYQKKQWY EIYDKYQVVQ TLDCLRYWKA THRSPGQIHL VQRHPPSEES
181 QAFQRQLTAL IGYDVTDVSN VHDDELEFTR RGLVTPRMAE VASRDPKLYA MHPWVTSKPL
241 PEYLWKKIAN NCIFIVIHRS TTSQTIKVSP DDTPGAILQS FFTKMAKKKS LMDIPESQSE
301 QDFVLRVCGR DEYLVGETPI KNFQWVRHCL KNGEEIHVVL DTPDPALDE VRKEEWPLVD
361 DCTGVTGYHE QLTIHGKDHE SVFTVSLWDC DRKFRVKIRG IDIPVLPRNT DLTVFVEANI
421 QHGQQVLCQR RTSPKPFTEE VLWNVWLEFS IKIKDLPKGA LLNLQIYCGK APALSSKASA
481 ESPSESCKGK VQLLYVNNLL LIDHRFLLRR GEYVLHMQI SGKGEDQGSF NADKLTSTAN
541 PDKENSMSIS ILLDNYCHPI ALPKHQTPD PEGDRVRAEM PNQLRKQLEA IIATDPLNPL
601 TAEDKELLWH FRYESLKHPK AYPKLFSSVK WGQQEIVAKT YQLLARREVW DQSALDVGLT
661 MQLLDCNFSD ENVRAIAVQK LESLEDDVLL HYLLQLVQAV KFEPYHDSAL ARFLLRGLR
721 NKRIGHFLFW FLRSEIAQSR HYQQRFAVIL EAYLRGCGTA MLHDFQQVQ VIEMLQKVTI
781 DIKSLSAEKY DVSSQVISQL KQKLENLQNS QLPESFRVPY DPGLKAGALA IEKCKVMASK
841 KKPLWLEFKC ADPTALSNET IGIIFKHGDD LRQDMLILQI LRIMESIWET ESLDLCLLPY
901 GCISTGDKIG MIEIVKDATT IAKIQQSTVG NTGAFKDEVL NHWLKEKSPT EEKFQAAVER
961 FVYSCAGYCV ATFVLGIGDR HNDNIMITET GNLFHIDFGH ILGNYKSFLG INKERVPFVL
1021 TPDFLFVMGT SGKKTSPHFQ KFQDICVKAY LALRHHTNLL IILFSMMLMT GMPQLTSKED
1081 IEYIRDALT V GKNEEDAKKY FLDQIEVCRD KGWTVQFNWF LHLVLGIKQG EKHSA

```

Recombinant P13 Kinase (p120y) nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgccatggg atccggaatt cgcccttgca tggagctgga gaactataaa
121 cagcccgtgg tgctgagaga ggacaactgc cgaaggcgcc ggaggatgaa gccgcgcagt
181 gctgcggcca gcctgtcctc catggagctc atccccatcg agttcgtgct gcccaccagc
241 cagcgcaaat gcaagagccc cgaacggcg cgtgctgcac tggccggcca cggcaacgtg
301 gagcagatga agggccaggt gtggctgcga gcgctggaga ccagcgtggc ggcggacttc
361 taccaccggc tgggaccgca tcacttcctc ctgctctatc agaagaagg gtcagtgttac
421 gagatctacg acaagtacca ggtggtgcag actctggact gcctgcgcta ctggaaggcc
481 acgcaccgga gcccgggcca gatcacctg gtgcagcggc acccgccctc cgaggagtcc
541 caagccttcc agcggcagct cagggcgctg attggctatg acgtcactga cgtcagcaac
601 gtgcacgacg atgagctgga gttcacgcgc cgtggccttg tgaccccgcg ctggcggag
661 gtggcgacgc gcgaccccaa gctctacgcc atgcaccgtg ggggtgacgtc caagcccctc
721 ccggagtacc tgtggaagaa gattgccaac aactgcatct tcatcgatc taccgcagc
781 accaccagcc agaccattaa ggtctcacc gacgacacc ccggcgccat cctgcagagc
841 ttcttcacca agatggccaa gaagaaatct ctgatggata ttcccgaaag ccaaagcgaa
901 caggattttg tgctgcgcgt ctgtggcgg gatgagtacc tgggtggcga aacgcccatc
961 aaaaacttcc agtgggtgag gcactgcctc aagaacggag aagagattca cgtggtactg
1021 gacacgcctc cagaccggc ctagacgag gtgaggaagg aagagtggc gctggtggac
1081 gactgcacgg gactcaccgg ctaccatgag cagcttacca tccacggcaa ggaccacgag

```

Certificate of Analysis

```

1141 agtgtgttca ccgtgtccct gtgggactgc gaccgcaagt tcagggtcaa gatcagaggc
1201 attgatatcc ccgtcctgcc tcggaacacc gacctcacag tttttgtaga ggcaaacatc
1261 cagcatgggc aacaagtcct ttgccaaagg agaaccagcc ccaaaccctt cacagaggag
1321 gtgctgtgga atgtgtggct tgagttcagt atcaaaatca aagacttgcc caaaggggct
1381 ctactgaacc tccagatcta ctgcggtaaa gctccagcac tgtccagcaa ggccctctgca
1441 gagtccccc gttctgagtc caagggcaaa gttcagcttc tctattatgt gaacctgctg
1501 ctgatatgacc accgtttcct cctgcgccgt ggagaatacg tcctccacat gtggcagata
1561 tctgggaagg gagaagacca aggaagcttc aatgctgaca aactcacgtc tgcaactaac
1621 ccagacaagg agaactcaat gtccatctcc attcttctgg acaattactg ccacccgata
1681 gccctgccta agcatcagcc caccctgac ccggaagggg accgggttcg agcagaaatg
1741 cccaaccagc ttgcgaagca attggaggcg atcatagcca ctgatccact taacctctc
1801 acagcagagg acaaaagaatt gctctggcat tttagatacg aaagccttaa gcacccaaaa
1861 gcatactcta agctatttag ttcagtgaag tggggacagc aagaaattgt ggccaaaaa
1921 taccaattgt tggccagaag ggaagtctgg gatcaaagtg ctttggatgt tgggttaaca
1981 atgcagctcc tggactgcaa cttctcagat gaaaatgtaa gagccattgc agttcagaaa
2041 ctggagagct tggaggacga tgatgttctg cattaccttc tacaattggt ccaggctgtg
2101 aaatttgaac cataccatga tagcgccctt gccagatttc tgctgaagcg tggtttaaga
2161 aacaaaagaa ttggtcactt tttgttttgg ttcttgagaa gtgagatagc ccagtccaga
2221 cactatcagc agaggttcgc tgtgattctg gaagcctatc tgaggggctg tggcacagcc
2281 atgctgcacg actttaccca acaagtccaa gtaatcgaga tgttacaaaa agtcaccctt
2341 gatattaaat cgctctctgc tgaaaagtat gacgtcagtt cccaagttaa ttcacaactt
2401 aaacaaaagc ttgaaaacct gcagaattct caactccccg aaagctttag agttccatat
2461 gatcctggac tgaaagcagg agcgtctggc attgaaaaat gtaaagtaat ggccccaag
2521 aaaaaaccac tatggcttga gtttaaatgt gccgatccta cagccctatc aaatgaaaca
2581 attggaatta tctttaaaca tgggtgatgat ctgcgccaag acatgcttat tttacagatt
2641 ctacgaatca tggagtctat ttgggagact gaatctttgg atctatgcct cctgccatat
2701 ggttgcatth caactggtga caaaatagga atgatcgaga ttgtgaaaga cgccacgaca
2761 attgcaaaaa ttcagcaaag cacagtgggc aacacgggag catttaaaaga tgaagtcctg
2821 aatcactggc tcaaagaaaa atcccctact gaagaaaagt ttcaggcagc agtggagaga
2881 tttgtttatt cctgtgcagg ctactgtgtg gcaacctttg ttcttggaaat aggcgcagaga
2941 cacaatgaca atattatgat caccgagaca ggaaacctat ttcattatga cttcgggcac
3001 attcttggga attacaaaag tttcctgggc attaataaag agagagtgcc atttgtgcta
3061 acccctgact tcctctttgt gatgggaact tctggaaaga agacaagccc acacttccag
3121 aaatttcagg acatctgtgt taaggcttat ctagcccttc gtcacacac aaacctactg
3181 atcatcctgt tctccatgat gctgatgaca ggaatgcccc agttaacaag caaagaagac
3241 attgaatata tccgggatgc cctcacagtg gggaaaaatg aggaggatgc taaaaagtat
3301 tttcttgatc agatcgaagt ttgcagagac aaaggatgga ctgtgcagtt taattggttt
3361 ctacatcttg ttcttggcat caaacaagga gagaacatt cagcctaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services